Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)
February 24, 2023 07:23 AM ESTUpdated 09:32 AM
R&D

No­var­tis re­treat from NASH takes down $80M al­liance with Pli­ant Ther­a­peu­tics

Amber Tong

Back in 2019, No­var­tis com­mit­ted $80 mil­lion to col­lab­o­rate with Pli­ant Ther­a­peu­tics on a pre­clin­i­cal can­di­date to treat liv­er fi­bro­sis as­so­ci­at­ed with non­al­co­holic steato­hep­ati­tis, or …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times